Quantcast
Last updated on April 21, 2014 at 10:27 EDT

Latest immunotherapies Stories

2011-10-04 09:44:00

DURHAM, N.C., Oct. 4, 2011 /PRNewswire/ -- Argos Therapeutics, Inc. today announced that its late scientific co-founder and scientific advisor Ralph M. Steinman, M.D., was awarded the Nobel Prize in medicine for the discovery of dendritic cells as critical sentinels of the immune system. Dr. Steinman's discovery of dendritic cells and his research of dendritic cell biology and the role of dendritic cells in adaptive immunity have led to the development of Argos' core technology,...

2011-08-10 06:00:00

LOS ANGELES, Aug. 10, 2011 /PRNewswire/ -- Genesis Biopharma, Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer immunotherapies, today announced it has signed a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute (NCI). Under the terms of the five-year cooperative research and development agreement, Genesis Biopharma will work with Steven A. Rosenberg, M.D., Ph.D., the NCI Surgery Branch Chief, to develop adoptive cell...

2010-09-10 11:45:04

Cancer immunotherapy calls for revised clinical endpoints that differ from those used for chemotherapy, according to an article published online September 8 in The Journal of the National Cancer Institute. Unlike chemotherapy, which acts directly on tumors, cancer immunotherapies exert their effects on the immune system, which may delay or change response patterns, perhaps owing to the dynamics of the immune system itself. For example, initial tumor burden may increase due to lymphocytic...

2010-04-29 12:55:00

SEATTLE, April 29 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that the U.S. Food and Drug Administration (FDA) has approved PROVENGE® (sipuleucel-T), an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer (CRPC). PROVENGE is designed to induce an immune response against prostatic acid phosphatase (PAP), an antigen expressed in...

2009-10-26 13:15:00

NEW YORK, Oct. 26 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue. Reportlinker Adds Immunotherapies and Vaccines for Nontraditional Indications http://www.reportlinker.com/p0155768/Reportlinker-Adds-Immunotherapies-and-Vaccines-for-Nontraditional-Indications.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=prnewswire Executive Summary The earliest immunotherapies were vaccines that stimulate the immune system's...

2009-04-28 13:00:00

- Extended Median Survival by 4.1 Months and Increased 3-Year Survival by 38 Percent Compared to Placebo - - First Active Cellular Immunotherapy for Cancer to Prolong Survival - - Company to Host Webcast at 5:30 pm ET - CHICAGO and SEATTLE, April 28 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that its pivotal Phase 3 IMPACT study of PROVENGE(R) (sipuleucel-T) in men with advanced prostate cancer met its primary endpoint of significantly improving overall...

2009-04-14 07:30:00

- Study Meets Primary Endpoint Showing Statistically Significant Improvement in Overall Survival - - First Active Immunotherapy for Cancer to Prolong Survival - - Full Data to be Presented at Plenary Session at Upcoming AUA Annual Meeting - - Company to Host a Conference Call Today at 9:00 AM ET - SEATTLE, April 14 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) announced today that the pivotal Phase 3 IMPACT study of PROVENGE(R) (sipuleucel-T) in men with advanced prostate...

2009-02-24 10:13:00

INDIANAPOLIS, Feb. 24 /PRNewswire/ -- PDS Biotechnology today announced that the company has obtained an exclusive license from Merck Eprova AG to utilize Merck Eprova's proprietary chiral lipid DOTAP Chloride in Versamune(TM)-HPV and other products in development based on the Versamune(TM) technology. The use of enantiomerically pure DOTAP Chloride shows enhanced adjuvant activity compared to the racemate. Merck Eprova AG will be providing enantiomerically pure DOTAP Chloride...

2008-10-31 09:00:28

Argos Therapeutics today announced the presentation of details on the Company's dendritic cell-based immunotherapy process, Arcelis(TM), as well as new research into the potential of the cytokine IL-12 as an immunopotency marker. The Company's Arcelis(TM) technology is a proprietary platform for creating personalized immunotherapies for HIV, other infectious diseases, and cancer. Don Healey, Ph.D., Director of Immunology at Argos, will present the poster today at the 23rd Annual Meeting of...

2008-10-21 09:00:54

Argos Therapeutics today announced the publication of a paper in the October 15th issue of the Journal of Immunonology demonstrating that the Company's proprietary RNA-electroporated dendritic cells generate high-avidity cytotoxic T cells (CTL) in vitro that are able to destroy cells expressing their target antigens. This advance may potentially improve the clinical benefit of dendritic cell-based immunotherapies for the treatment of infectious disease and cancer. This approach is part of the...